

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the month of September 2024**

Commission File Number: **001-39777**

**Nanobiotix S.A.**

(Translation of registrant's name into English)

**60 Rue de Wattignies 75012 Paris, France**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

---

On September 3, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[\(c\) Exhibit 99.1. Press release dated September 3, 2024](#)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Nanobiotix S.A.

(Registrant)

Date: September 3, 2024

/s/ Bart Van Rhijn

Bart Van Rhijn  
Chief Financial Officer

## Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBOTIX (Euronext: NANO — NASDAQ: NBTX – the “**Company**”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming H.C. Wainwright 26<sup>th</sup> Annual Global Investment conference. Please see below for details of the event.

### H.C. Wainwright 26<sup>th</sup> Annual Global Investment conference

Date: Wednesday, September 11, 2024

Time: 9:30 AM EDT / 3:30 PM CEST

Location: New York, NY

Presenters: Laurent Levy, co-founder of Nanobiotix and chairman of the executive board & Bart Van Rhijn, chief financial officer of Nanobiotix

Webcast link: [Click here](#)

The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. Replay of the webcast will be available following the event.

### About NANOBOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on LinkedIn and Twitter.

### Contacts

---

#### *Nanobiotix*

---

#### **Communications Department**

*Brandon Owens*

*VP, Communications*

+1 (617) 852-4835

[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

#### **Investor Relations Department**

*Craig West*

*SVP, Investor Relations*

+1 (617) 583-0211

[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

---

#### *Media Relations*

---

#### **FR – Ulysse Communication**

*Pierre-Louis Germain*

+ 33 (0) 6 64 79 97 51

[plgermain@ulysses-communication.com](mailto:plgermain@ulysses-communication.com)

#### **Global – LifeSci Advisors**

*Kevin Gardner*

+1 (617) 283-2856

[kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)

### Attachment

- 2024-09-03 -- NBTX -- Presenting @ HCW&Co -- FINAL (<https://ml.globenewswire.com/Resource/Download/2aceec6d-49e8-4096-9cd8-10c2da0e8479>)